Welcome to HitGen

Available now!
Whitepaper:Advancing Drug Discovery through DNA Encoded Library Technology

Read more

OpenDEL®: Making DNA-Encoded Library Screening Broadly Available

Read more

Advancing Innovative Drug Discovery

Read more

Drug discovery, it's in our DNA.

Read more

Enable Innovative Drug Discovery with DEL, FBDD and SBDD

Read more

Capabilities & Services

Enabling Innovative Drug Discovery with Advanced Technologies

  • DNA-encoded Library
    DNA-encoded Library
  • Fragment-based Drug Discovery
    FBDD/SBDD
  • Chemistry
    Chemistry
  • Bioscience
    Bioscience
  • Computational Sciences and Informatics
    Computational Sciences and Informatics
  • Structural Biology
    Structural Biology
  • Pre-clinical Studies
    Pre-clinical Studies
  • Clinical Development
    Clinical Development

Therapeutic Areas

Integrated One-stop Drug Discovery Platform   Accelerating Project with High Efficiency

  • Oncology and Immuno-oncology
    Oncology and Immuno-oncology
  • Inflammatory and Autoimmune Diseases
    Inflammatory and Autoimmune Diseases
  • Ophthalmology
    Ophthalmology
  • Infectious Diseases
    Infectious Diseases
  • Metabolic Diseases
    Metabolic Diseases
  • Cardiovascular Diseases
    Cardiovascular Diseases
HitGen Inc. is a rapidly developing biotech company
The discovery and development of novel medicines and agrochemicals
>1 Trillion

DNA encoded compounds

>6,000

novel drug/target complex structures for FBDD/SBDD

About Us

HitGen Inc. is a biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH).  HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.

 

Through its acquisition of Cambridge UK based Vernalis R&D Ltd before the end of 2020, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing.

 

HitGen RNA therapeutics R&D platform includes key capabilities such as bioinformatics, organic chemistry and medicinal chemistry,RNA biology, molecular biology and cell biology, translational research and clinical research. The platform not only provides high quality services to support internal and external RNA therapeutics R&D projects, but also carries out siRNA sequence design, siRNA parallel synthesis and chemical modification/conjugation, mRNA and protein knock-down assays in both engineered cell lines and primary cell lines, stability test, off-target assessment, bio-distribution and other relate in vitro/in vivo assays for activity and toxicity study, etc. HitGen has also established its own pipelines in early stages to discover novel RNA therapeutics, aiming for providing new treatment for unmet medical needs in oncology and immunology.

 

HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS,e.g., protein expression and purification, structural biology, bioinformatics, computational chemistry, medicinal chemistry, nucleic and organic chemistry, analytical chemistry, biophysics, PK, PD, etc.), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing. HitGen has approximately 20 in-house drug discovery programs at different stages of research & development. At present, 4 programs have obtained IND approvals by NMPA and entered into clinical trials. HitGen is collaborating with pharmaceutical, biotech and chemical companies, foundations and research institutes in North America, Europe, Asia, Africa and Australia to enable the discovery and development of novel medicines and agrochemicals.


For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: media@hitgen.com

For investor inquiries: investors@hitgen.com  

For business development: bd@hitgen.com  


Read More

Collaboration Partners

Latest News

  • 23 December 2021

    Lipigon and HitGen extend collaboration agreement on dyslipidemia project

    Chengdu, China December 23, 2021 Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, and HitGen Inc. (”HitGen”) have extended the collaboration agreement on the development of small molecules for the treatment of dyslipidemia and cardiometabolic disease until 7 July 2024.
    + Read More
  • 05 November 2021

    HitGen and Cambridge Molecular announce a strategic partnership, bringing together DNA-Encoded Libraries and Deep Learning

    Chengdu, China, and Cambridge, United Kingdom, 5 November 2021 – HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.
    + Read More
  • 01 November 2021

    Vernalis Research - a fully owned subsidiary of HitGen Inc - and Hannibal Innovation announce the creation of Dania Therapeutics ApS

    Chengdu, China, 1 November 2021 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS (“Hannibal”) are pleased to announce the creation of Dania Therapeutics ApS (“Dania”) to discover small molecules inhibitors against new undisclosed oncology targets.
    + Read More
Investors

Latest Announcements,
Financial News and Stock Information

Read More

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information